Pomerantz Law Firm Launches Investigation into Viking Therapeutics Investors' Claims

Investigation into Viking Therapeutics

Pomerantz LLP, a leading law firm known for its extensive experience in corporate, securities, and antitrust class litigation, is currently pursuing an investigation on behalf of investors associated with Viking Therapeutics, Inc. (NASDAQ: VKTX). The investigation focuses on potential securities fraud or other illicit business activities involving the company's officers and directors.

The scrutiny stems from Viking's recent press release detailing positive trial results for VK2735, an anti-obesity drug, which was presented during the Obesity Week medical meeting on November 3, 2024. Initially, this announcement led to a significant surge in Viking's stock price, which saw an impressive 9% increase on intraday trading the following day. However, this bullish sentiment was short-lived. Analysts soon raised concerns regarding the feasibility of scaling up production, particularly for higher doses of the drug, which could pose a substantial obstacle for Viking’s future profitability.

In fact, Deutsche Bank analysts warned that the costs associated with manufacturing VK2735 would be considerably high and might exceed the capital capabilities and expertise of the company's current partners, including giants like Eli Lilly and Novo Nordisk. The resultant skepticism from analysts triggered a sharp decline in Viking's stock value, which plummeted by 13.36%, closing at $63.14 on November 4, 2024. This downward trend prompted Pomerantz LLP to act swiftly in order to protect the interests of investors.

Given the volatility in Viking’s stock performance and the stock market's response, investors who feel adversely impacted are being encouraged to reach out to Pomerantz LLP for potential involvement in a class-action lawsuit. Attorney Danielle Peyton is handling these inquiries and can be contacted directly at the firm's New York offices.

With over 85 years of experience, Pomerantz LLP continues to build upon the legacy of its founder, Abraham L. Pomerantz, who was a pioneer in securities class actions. The firm has made significant recoveries for class members, amounting to billions in damages awarded in past cases. Their commitment remains steadfast: to advocate for those who have suffered from securities fraud, breaches of fiduciary duty, and corporate misconduct.

As the investigation unfolds, it underscores a critical reminder for investors: due diligence and awareness are paramount in navigating the complexities of the stock market. The outcomes of such investigations could set precedents and pave the way for enhanced corporate accountability in the future, serving as a beacon of hope for investors facing potential losses.

For those interested in following this case or who want more information about filing a claim, they can visit Pomerantz LLP’s website or contact Danielle Peyton directly via the provided email or phone number.